

Drug Pricing Policy Summit: Measuring Progress and Making Our Mark November 15-16, 2017 Japanese Canadian Cultural Centre, 6 Garamond Court, Toronto, Ontario

AGENDA DAY 1 - WEDNESDAY NOVEMBER 15, 2017

8.30-9.00	Breakfast and registration
9.00-9.10	Welcome Address Kathy Barnard, President & CEO, Save Your Skin Foundation
9.10-9.20	Overview of Summit Agenda Sophie Wertheiner, Summit Facilitator
9.20-10.30	Keynote Panel: Light at the end of the Tunnel: Value Based Health Outcomes Measurement
10.30-10.50	 Louise Binder, Health Policy Consultant, Save Your Skin Foundation – Introductory remarks Andre Dias, Head of Regulatory and Commercial, Myia Labs Fred Horne, Principal, Horne and Associates, and Senior Advisor, 3 Sixty Public Affairs, and Former Minister of Health, Alberta (2011-2014) Terri Lohnes, Vice President and Practice Lead, Public Sector, Healthcare and Not-For-Profit Group, Optimus ISBR Patient Perspectives: So what does this really mean to patients?
	 Martine Elias, Director Access, Advocacy and Community Relations, Myeloma Canada Phil Upshall, Senior Policy Advisor, Mood Disorders Society of Canada Linda Wilhelm, President, Canadian Arthritis Patient Alliance
10.50-11.00	Q&A
11.00-11.15	BREAK
11.15-12.00	Working Committees: What have we been up to since last year?
12.00-13.00	LUNCH
13.00-14.00	PANEL 2: What's Hot and What's Not Under "Sunny Ways"?

- Michèle Chadwick, Lead, Regulatory Review of Drugs and Devices, Health Canada
- Wayne Critchley, Senior Associate, Global Public Affairs Health & Life Sciences
- Sarah Berglas, Patient Engagement Officer, Canadian Agency for Drugs and Technologies in Health (CADTH)

14.00-14.10	Patient Perspectives: What does this mean for patient access?
14.10-14.20	Q&A
14.20-14.45	Patient Roundtable Discussion
14.45-15.00	BREAK
15.00-16.00	 PANEL 3: Not such "Sunny Ways" for Those Who Write the Cheques? Imran Ali, Senior Manager, pan-Canadian Pharmaceutical Alliance Office Sylvie Bouchard, Director of Medication, Institut national d'excellence en santé et en services sociaux Dr. Kim Critchley, Deputy Minister, Health and Wellness, Province of Prince Edward Island Chad Mitchell, Executive Director, Pharmaceutical and Health Benefits, Alberta Health
16.00-16.10	Patient Perspectives: Sunny or rainy days for patient access?
16.10-16.20	Q&A
16.20-16.45	Patient Roundtable Discussion
16.45-17.00	Wrap-up of Day 1



AGENDA DAY 2 - THURSDAY NOVEMBER 16, 2017

Breakfast and registration

8.30-9.00

9.00-9.10	Welcome Address – Day 2
9.10-10.10	PANEL 4: Creative Ideas to Manage Cost and Sustainability
	 John Law, Global Director of Benefits & Director, Total Rewards (Americas), Pitney Bowes Inc. Noel MacKay, Principal Consultant, National Benefits, The Williamson Group Joan Weir, Director, Health and Disability Policy, Canadian Life and Health Insurance Association
10.10-10.20	Patient Perspectives: What does this mean to patients?
10.20-10.30	Q&A
10.30-10.45	BREAK

PANEL 5: Implications for the Pharmaceutical Industry in Canada 10.45-11.45 Kim Furlong, Director, Federal Government Affairs and Policy, Amgen Canada Ilias Iliopoulos, Associate Director, Patient Access Ontario and Federal, Merck Canada Inc. Mark Legault, Director, Market Access & Strategic Pricing, Pfizer Canada 11.45-11.55 Patient Perspectives: What do these changes mean for access? 11.55-12.05 Q&A 12.05-13.00 LUNCH PANEL 6: How do We Get There from Here? Words to the Wise 13.00-14.00 Alan Birch, Drug Access Facilitator, North York General Hospital Jamie Keller, Assistant Professor – Teaching Stream Leslie Dan, Faculty of Pharmacy, University of Toronto Dr. Sandy Sehdev, Medical Oncologist 14.00-14.10 Q&A 14.10-14.25 **Observer High Level Perspectives and Observations** 14.25-14.40 **BREAK**

Priority Setting and Next Steps (Draft 2017-2018 action plan review and Committee sign up)

14.40-15.40

15.40-16.35

16.35-16.45

Group Work

Summit Wrap Up and Evaluation

